Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
RIGGS STEVEN
   2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ICUI] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP Operations
(Last)
(First)
(Middle)
951 CALLE AMANECER		 3. Date of Earliest Transaction (Month/Day/Year)
09/12/2016
(Street)

SAN CLEMENTE, CA 92673		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/12/2016   S(1)   703 (2) D $ 121.3164 (3) 675 D  
Common Stock (4) 09/12/2016   S(1)   675 D $ 121.3452 (5) 0 D  
Common Stock 09/12/2016   X   13,634 A $ 58.79 13,634 D  
Common Stock 09/12/2016   S(1)   10,250 D $ 121.7634 (6) 3,384 D  
Common Stock 09/12/2016   S(1)   3,384 D $ 122.0596 (7) 0 D  
Common Stock 09/12/2016   X   12,833 A $ 58.79 12,833 D  
Common Stock 09/12/2016   S(1)   11,333 D $ 121.7565 (8) 1,500 D  
Common Stock 09/12/2016   S(1)   1,500 D $ 122.064 (9) 0 D  
Common Stock 09/12/2016   X   11,957 A $ 58.79 11,957 D  
Common Stock 09/12/2016   X   2,460 A $ 61.76 14,417 D  
Common Stock 09/12/2016   S(1)   11,717 D $ 121.7447 (10) 2,700 D  
Common Stock 09/12/2016   S(1)   2,700 D $ 122.0659 (11) 0 D  
Common Stock 09/13/2016   X   800 A $ 58.79 800 D  
Common Stock 09/13/2016   S(1)   800 D $ 121.89 (12) 0 D  
Common Stock 09/13/2016   X   1,677 A $ 58.79 1,677 D  
Common Stock 09/13/2016   S(1)   1,677 D $ 121.3477 (13) 0 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $ 58.79 09/12/2016   X     13,634   (14) 02/24/2024 Common Stock 13,634 $ 58.79 (15) 89,767 D  
Non-Qualified Stock Option (right to buy) $ 58.79 09/12/2016   X     12,833   (14) 02/24/2024 Common Stock 12,833 $ 58.79 (15) 76,934 D  
Non-Qualified Stock Option (right to buy) $ 58.79 09/12/2016   X     11,957   (14) 02/24/2024 Common Stock 11,957 $ 58.79 (15) 64,977 D  
Non-Qualified Stock Option (right to buy) $ 58.79 09/13/2016   X     800   (14) 02/24/2024 Common Stock 800 $ 58.79 (15) 64,177 D  
Non-Qualified Stock Option (right to buy) $ 58.79 09/13/2016   X     1,677   (14) 02/24/2024 Common Stock 1,677 $ 58.79 (15) 62,500 D  
Non-Qualified Stock Option (right to buy) $ 61.76 09/12/2016   X     2,460   (16) 02/06/2023 Common Stock 2,460 $ 61.76 (15) 3,446 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
RIGGS STEVEN
951 CALLE AMANECER
SAN CLEMENTE, CA 92673		       VP Operations  

Signatures

 By: Paula Darbyshire For: Steven C. Riggs   09/13/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on August 11, 2016.
(2) Shares purchased through Employee Stock Purchase Plan.
(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.14 to $121.31, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(4) These securities are Restricted Stock Units.
(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.14 to $121.70, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.00 to $121.99, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.00 to $122.15, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.04 to $122.03, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.04 to $122.10, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.97 to $121.96, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(11) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.99 to $122.18, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(12) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.75 to $122.13, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(13) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $122.19, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
(14) Twenty-five percent of the shares shall vest on each of the first, second,third, and fourth anniversaries of the grant date . Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of eh exercise price for 30 consecutive trading days.
(15) Transaction is the exercise of a derivative security; see Column 2.
(16) Options vest and are exercisable as to 25% of the underlying grant one year after the date of grant and in equal monthly installments thereafter for three additional years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.